Press Releases

 
Press Releases
  Date Title and Summary View
Nov 14, 2017
AMES, Iowa, Nov. 14, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Eugene P. Kennedy, M.D., FACS, to the role of Chief Medical Officer. He will be responsible for leading all clinical development, medical affairs and related functions. Dr. Kennedy's previous role at NewLink Genetics was Vic...
Nov 13, 2017
AMES, Iowa, Nov. 13, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) will participate in the following investor conferences this week: Stifel 2017 Healthcare Conference on Tuesday, November 14th, at 5:00pm ET in New York CityJefferies 2017 London Healthcare Conference on Thursday, November 16th, at 17:20 GMT (12:20pm ET) ...
Nov 2, 2017
AMES, Iowa, Nov. 02, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the third quarter of 2017 and provided updates on its clinical development program for indoximod, NewLink Genetics' IDO pathway inhibitor with a distinct mechanism of action. "We are pleased with the prog...
Oct 30, 2017
AMES, Iowa, Oct. 30, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that indoximod, its leading drug development candidate, was granted orphan-drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Stage IIb-IV melanoma.  "We are pleased to receive this orphan d...
Oct 20, 2017
AMES, Iowa, Oct. 20, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its third quarter 2017 financial results on Thursday, November 2, 2017. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on its clinical and development a...
Oct 3, 2017
AMES, Iowa, Oct. 03, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation ("NewLink Genetics") (Nasdaq:NLNK), a late-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $10.25 per share.  All of the shares of common stock to be sold i...
Oct 3, 2017
AMES, Iowa--(BUSINESS WIRE)-- NewLink Genetics Corporation ("NewLink Genetics") (Nasdaq:NLNK), a late-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market conditions, up to $50,000,000 of shares of its common stock in an underwritten public offering. All of ...
Sep 25, 2017
Phase 2, randomized, double-blind, placebo-controlled trial of indoximod in combination with durvalumab, an immune checkpoint inhibitor, along with gemcitabine/ABRAXANE® (nab-paclitaxel) and durvalumab with gemcitabine/ABRAXANE® versus gemcitabine/ABRAXANE® AMES, Iowa...
Sep 7, 2017
Pivotal Trial of Indoximod in Advanced Melanoma to Include Both PD-1 Inhibitors, KEYTRUDA (pembrolizumab) and OPDIVO® (nivolumab) AMES, Iowa--(BUSINESS WIRE)-- NewLink Genetics Corporation (NASDAQ: NLNK) today announced updated data from the ongoing Phase 2 NLG2103 stu...
Aug 29, 2017
AMES, Iowa, Aug. 29, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the following investor conferences in September: Baird Global Healthcare Conference on September 7 at 1:25pm ET in New York CityCantor Fitzgerald Global Healthcare Conference on September 25 at 4:10pm ET in New...
Page:
1
... NextLast
= add release to Briefcase